Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyowa kirin co.,ltd - darbepoetin alfa (genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyowa kirin co.,ltd - darbepoetin alfa (genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyowa kirin co.,ltd - darbepoetin alfa (genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyowa kirin co.,ltd - darbepoetin alfa (genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyowa kirin co.,ltd - darbepoetin alfa (genetical recombination) - injection

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

European Union - English - EMA (European Medicines Agency)

dompé biotec s.p.a. - darbepoetin alfa - kidney failure, chronic; anemia; cancer - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients.treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

European Union - English - EMA (European Medicines Agency)

amgen europe b.v. - darbepoetin alfa - anemia; cancer; kidney failure, chronic - other antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients.treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy